Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

88.4K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.4K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanochemical Methods for Amide Bond Formation.

Chemical reviews·2026
Same author

The Interplay Between Physical Exercise, Nutritional Strategies, and Brain-Derived Neurotrophic Factor in Promoting Cognitive Performance.

Aging and disease·2026
Same author

Making of BDNF: role of promoters, enhancers, and untranslated regions.

Trends in neurosciences·2026
Same author

The E-Protein Daughterless Regulates Olfactory Learning of Adult <i>Drosophila melanogaster</i>.

eNeuro·2026
Same author

CISD2 ensures adequate ER-mitochondrial coupling, critically supporting mitochondrial function in neurons.

Acta neuropathologica communications·2025
Same author

Mechanochemistry: A Transformative Technique for the Synthesis of Polar Organometallics from Zero-Valent Metals.

ChemPlusChem·2025

Related Experiment Video

Updated: Mar 19, 2026

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
07:30

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

Published on: January 21, 2020

8.8K

Indole-like Trk receptor antagonists.

Jaana Tammiku-Taul1, Rahel Park2, Kaur Jaanson2

  • 1University of Tartu, Institute of Chemistry, Ravila 14A, Tartu, 50411, Estonia; Tallinn University of Technology, Department of Chemistry, Akadeemia 15, Tallinn, 12618, Estonia.

European Journal of Medicinal Chemistry
|June 20, 2016
PubMed
Summary

Researchers identified novel low molecular weight drug candidates targeting TrkA receptors for neuropathic pain and cancer. A synthesized sulfonamide derivative demonstrated potent TrkA, TrkB, and TrkC inhibition, showing promise for therapeutic applications.

Keywords:
2-OxindoleAntagonistFragment-based QSARTrkATrkB

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

3.1K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 19, 2026

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
07:30

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

Published on: January 21, 2020

8.8K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

3.1K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Computational Chemistry

Background:

  • Neuropathic pain and cancer represent significant unmet medical needs.
  • TrkA receptor signaling is implicated in both pain pathways and tumor progression.
  • Targeting Trk receptors offers a potential therapeutic strategy for these conditions.

Purpose of the Study:

  • To identify novel low molecular weight TrkA receptor antagonists.
  • To design and synthesize new compounds based on structure-activity relationships (SAR).
  • To evaluate the inhibitory potential of novel compounds against Trk receptors.

Main Methods:

  • Virtual screening was employed to identify potential drug scaffolds.
  • Quantitative Structure-Activity Relationship (QSAR) models (molecular and fragment-based) were used for IC50 prediction.
  • Structure-activity relationships (SAR) guided the design and synthesis of new chemical entities.
  • Biochemical and cellular assays were utilized to assess TrkA inhibitory activity.

Main Results:

  • Virtual screening identified promising scaffolds for TrkA antagonists.
  • A series of novel compounds were designed and synthesized based on SAR.
  • (Z)-3-((5-methoxy-1-methyl-1H-indol-3-yl)methylene)-N-methyl-2-oxindole-5-sulfonamide exhibited potent TrkA inhibition in biochemical and cellular assays.
  • (Z)-3-((5-methoxy-1-methyl-1H-indol-3-yl)methylene)-2-oxindole-5-sulfonamide demonstrated the highest potency against TrkB and TrkC receptors.

Conclusions:

  • Novel low molecular weight drug candidates targeting TrkA receptors were discovered.
  • The synthesized sulfonamide derivative is a potent inhibitor of TrkA, TrkB, and TrkC receptors.
  • These findings support the therapeutic potential of Trk receptor antagonists for neuropathic pain and cancer treatment.